Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

CymaBay Therapeutics

company

About

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
$27M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 1991
Number Of Employee
51 - 100
Operating Status
Active

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.

Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$111.60M
CymaBay Therapeutics has raised a total of $111.60M in funding over 2 rounds. Their latest funding was raised on Nov 5, 2009 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 5, 2009 Series E $8.60M 1 Detail
Apr 19, 2007 Series D $32M 2 Detail
Dec 1, 2004 Series B $44M 1 Detail
Aug 29, 2003 Series A $27M 3 Detail

Investors

Number of Lead Investors
Number of Investors
4
CymaBay Therapeutics is funded by 4 investors. Versant Ventures and Biotech Turnaround Fund (BTF) are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Series E
Biotech Turnaround Fund (BTF) Series D
Charter Venture Group Series A
CDP Capital Technology Ventures Series A